Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX14 vs Prolia in Postmenopausal Osteoporosis at High Fracture Risk
CTR20220557Phase 3Completed
- Sponsor
- Fosun Pharma
- Start
- Mar 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of denosumab-nxxp in osteoporosis (2 arms), sponsored by Fosun Pharma. Primary endpoint: Percent change in lumbar spine BMD from baseline to Week 52 (Day 365). Started Mar 2022; status: completed.
02
Drugs
denosumab-nxxp
03
Conditions
osteoporosis
Beyond the preview
Go deeper on CTR20220557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220557.